Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
ISLR Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ISLR Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ISLR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JCHAIN Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JCHAIN Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of JCHAIN sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KDELR2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KDELR2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KDELR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KDELR1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KDELR1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KDELR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ISLR2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ISLR2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ISLR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGSF23 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGSF23 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGSF23 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IMPG1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IMPG1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IMPG1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGSF3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGSF3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGSF3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGSF6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGSF6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGSF6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGSF8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGSF8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGSF8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV8-61 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV8-61 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV8-61 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV9-49 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV9-49 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV9-49 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →